Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

This study has been completed.
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ryan Sullivan, M.D., Massachusetts General Hospital Identifier:
First received: March 1, 2010
Last updated: June 7, 2016
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)